

Resource Summary Report

Generated by T1D on Sep 21, 2026

Finnish Cancer Registry

RRID:SCR_005881

Type: Tool

Proper Citation

Finnish Cancer Registry (RRID:SCR_005881)

Resource Information

URL: <http://www.cancer.fi/syoparekisteri/en/>

Proper Citation: Finnish Cancer Registry (RRID:SCR_005881)

Description: The Finnish Cancer Registry maintains a nation-wide database on all cancer cases in Finland going back to 1953. It is also an internationally active institute for statistical and epidemiological cancer research. The Mass Screening Registry is a department of the Finnish Cancer Registry, and is responsible of planning and evaluating national cancer screening programs in Finland. The site contains information on cancer research and up to date statistics on the prevalence of different types of cancer in Finland, the Nordic countries and on a global level. The web pages include information for participants in cancer screening and for professionals involved in organizing such screening.

Abbreviations: Finnish Cancer Registry

Resource Type: institution

Related Condition: Cancer

Funding: Cancer Society of Finland

Resource Name: Finnish Cancer Registry

Resource ID: SCR_005881

Alternate IDs: grid.424339.b, nlx_149446, ISNI: 0000 0000 8634 0612

Alternate URLs: <https://ror.org/00j15sg62>

Record Creation Time: 20220129T080233+0000

Record Last Update: 20260919T195101+0000

Ratings and Alerts

No rating or validation information has been found for Finnish Cancer Registry.

No alerts have been found for Finnish Cancer Registry.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#).

Pylväläinen J, et al. (2024) Risk of Clinically Significant Prostate Cancer after a Nonsuspicious Prostate MRI-A Comparison with the General Population. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 33(5), 749.

Llewellyn-Bennett R, et al. (2018) Post-trial follow-up methodology in large randomised controlled trials: a systematic review. Trials, 19(1), 298.

Saraswat M, et al. (2017) Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis. Cancer medicine, 6(7), 1738.

Uusitalo E, et al. (2017) Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. British journal of cancer, 116(2), 211.

Ricker CA, et al. (2016) Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Frontiers in oncology, 6, 259.

Singh D, et al. (2015) Association of symptoms and breast cancer in population-based mammography screening in Finland. International journal of cancer, 136(6), E630.

Siltanen S, et al. (2013) ARLTS1 and prostate cancer risk--analysis of expression and regulation. PloS one, 8(8), e72040.

Tolppanen AM, et al. (2013) Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the Medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clinical epidemiology, 5, 277.